Show simple item record

dc.contributor.authorSecrier, M
dc.contributor.authorLi, X
dc.contributor.authorde Silva, N
dc.contributor.authorEldridge, MD
dc.contributor.authorContino, G
dc.contributor.authorBornschein, J
dc.contributor.authorMacRae, S
dc.contributor.authorGrehan, N
dc.contributor.authorO'Donovan, M
dc.contributor.authorMiremadi, A
dc.contributor.authorYang, T-P
dc.contributor.authorBower, L
dc.contributor.authorChettouh, H
dc.contributor.authorCrawte, J
dc.contributor.authorGaleano-Dalmau, N
dc.contributor.authorGrabowska, A
dc.contributor.authorSaunders, J
dc.contributor.authorUnderwood, T
dc.contributor.authorWaddell, N
dc.contributor.authorBarbour, AP
dc.contributor.authorNutzinger, B
dc.contributor.authorAchilleos, A
dc.contributor.authorEdwards, PAW
dc.contributor.authorLynch, AG
dc.contributor.authorTavare, S
dc.contributor.authorFitzgerald, RC
dc.date.accessioned2021-04-26T01:16:19Z
dc.date.available2021-04-26T01:16:19Z
dc.date.issued2016-10-01
dc.identifierpii: ng.3659
dc.identifier.citationSecrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O'Donovan, M., Miremadi, A., Yang, T. -P., Bower, L., Chettouh, H., Crawte, J., Galeano-Dalmau, N., Grabowska, A., Saunders, J., Underwood, T., Waddell, N. ,... Fitzgerald, R. C. (2016). Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. NATURE GENETICS, 48 (10), pp.1131-1141. https://doi.org/10.1038/ng.3659.
dc.identifier.issn1061-4036
dc.identifier.urihttp://hdl.handle.net/11343/269346
dc.description.abstractEsophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.titleMutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
dc.typeJournal Article
dc.identifier.doi10.1038/ng.3659
melbourne.affiliation.departmentCentre for Cancer Research
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleNature Genetics
melbourne.source.volume48
melbourne.source.issue10
melbourne.source.pages1131-1141
melbourne.elementsid1103948
melbourne.openaccess.urlhttps://europepmc.org/articles/PMC5957269?pdf=render
melbourne.openaccess.statusPublished version
dc.identifier.eissn1546-1718
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record